Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Capital International Investors

Capital International Investors lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 7,127,913 shares of the medical equipment provider’s stock after selling 422,841 shares during the quarter. Capital International Investors’ holdings in Zimmer Biomet were worth $640,942,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Key Financial Inc increased its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $32,000. Grove Bank & Trust increased its stake in shares of Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $37,000. Finally, Basepoint Wealth LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE ZBH opened at $87.50 on Monday. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The firm has a market capitalization of $16.93 billion, a PE ratio of 22.73, a P/E/G ratio of 2.02 and a beta of 0.47. The company’s 50 day simple moving average is $87.68 and its 200 day simple moving average is $90.49.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the business earned $1.81 earnings per share. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating on the stock. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Truist Financial reiterated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Leerink Partners initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $102.70.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.